News Eikon, Veradermics close IPOs, as Salspera joins queue Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.
News Three more biotechs price their Nasdaq IPOs AgomAb, SpyGlass, and Veradermics have all set the terms for their IPOs this week, looking to raise somewhere between around $150m and $200m.
News Perlmutter's Eikon follows the IPO trail Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
News Lila Sciences' swollen first round, and other biofinancings AI-powered autonomous lab firm Lila Sciences upsizes its Series A to $350m, heading a bumper week for new biotech financings.
News Carlyle backs Essential refinancing and other funding news Essential Pharma announces a €900m recapitalisation deal, while Noema Pharma, Angitia Biopharma, Citryll, and Veradermics also raise new cash.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.